February 8, 2018 | Arizona Biltmore | Phoenix, Arizona

Amelia Gallitano, M.D., Ph.D
Associate Professor, Department of Basic Medical Sciences
Associate Professor, Department of Psychiatry
University of Arizona College of Medicine-Phoenix

Amelia Gallitano, M.D., Ph.D. received her medical degree, and Ph.D. in Neuroscience, from The University of Pennsylvania School of Medicine. She completed residency training in Psychiatry at Columbia University and the New York State Psychiatric Institute, followed by a post-doctoral research fellowship at Washington University School of Medicine in St. Louis, where she was a faculty member in the Department of Psychiatry. She is a board-certified psychiatrist.

Dr. Gallitano joined the University of Arizona College of Medicine (UACOM) as one of the founding faculty members of the Phoenix campus in 2007. Since starting her laboratory there she has received numerous awards and grants, including the first National Institute of Health R01 grant awarded to an Assistant Professor in the department of Basic Medical Sciences (BMS). She is currently an Associate Professor with Tenure in the Department of BMS at the UACOM – Phoenix, and Associate Professor of Psychiatry, and the Interdisciplinary Graduate Program in Neuroscience, at the UACOM. She also holds adjunct positions as an Associate Professor of Neuroscience at Arizona State University and an Investigator at the Translational Genomics Research Institute. Her research focuses on investigating how immediate early genes may mediate the interaction of environmental stress and genetic predisposition to influence the development of psychiatric illnesses such as schizophrenia.

Presentation: A Translational Approach to Develop a Novel, Biologically-Based, Diagnostic Test for Schizophrenia

What You Will Learn:

• Identify a type of brain neurotransmitter receptor that mediates sedation.
• Describe how changes in levels of the neurotransmitter in the brain may influence the sedation response to antipsychotic medications.
• Recognize how levels of this receptor are altered in the brains of schizophrenia patients.